European regulators approve Zoetis’ Simparica Trio
The monthly chewable kills fleas, ticks and intestinal worms and prevents heartworm disease.
A newly approved multipurpose antiparasitic medication from Zoetis Inc. will be sold to European dog owners starting in early 2020.
The product, Simparica Trio (sarolaner/moxidectin/pyrantel), is a chewable tablet formulated to kill fleas, ticks, roundworms and hookworms and to prevent heartworm disease and lungworm disease.
Given monthly, the drug earned European Commission approval and is expected to be launched across the European Union during the first quarter.
“The convenience of a once-monthly chewable tablet helps increase compliance with treatment, giving veterinarians and dog owners confidence in continuous protection,” said Domenico Otranto, DVM, Ph.D., DEVPC, a professor of veterinary parasitology and a Zoetis consultant.
Simparica Trio is effective for five weeks against two species of fleas and the hedgehog tick, castor bean tick and brown dog tick. The drug has a four-week efficacy against the ornate cow tick, Zoetis reported.
“It demonstrated a rapid onset of action, killing fleas before they have a chance to lay eggs and can be used as part of a treatment strategy for the control of flea allergy dermatitis,” the company stated.
The active ingredients are sarolaner, for fleas and ticks; moxidectin, for heartworm, lungworm and some intestinal worms; and pyrantel embonate, for hookworms and roundworms.
Simparica Trio will come in six dosages and is indicated for dogs at least 8 weeks old and weighing at least 2.75 pounds.